|Myriad's Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk; FDA Approves JANUMET XR|
|By Mary Davila|
|Thursday, 02 February 2012 20:12|
Myriad Genetics, Inc. (Nasdaq: MYGN) announced a presentation entitled, "Validation of a panel of cell-cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," was presented on Thursday, February, 2, 2012 at the 2012 Genitourinary Cancers Symposium.
The study concluded that the Prolaris score, which analyzes the expression level of 46 cell cycle progression genes, demonstrated significant and unique prognostic ability in a contemporary cohort of men who had undergone radical prostatectomy, and accurately predicted their elevated risk for prostate cancer recurrence.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the FDA approved JANUMET^ XR (sitagliptin and metformin hydrochloride (HCl) extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA^ (sitagliptin), with extended-release metformin.
JANUMET XR provides a convenient once-daily treatment option for healthcare providers and patients who need help to control their blood sugar.
MissionIR today announces that its interview with Boyd Gentry, the president and chief executive officer of AdCare Health Systems (NYSE Amex: ADK), is now available online.
MWI Veterinary Supply, Inc. (NASDAQ: MWIV) (the "Company") announced financial results today for its first quarter ended December 31, 2011.
PHI Group, Inc. (OTCQB: PHIE) (PINKSHEETS: PHIE) announced today that Humex Medical Group, Inc. has signed an agreement with Tri Phuoc Co., Ltd, a Vietnamese company, to establish a stem cell center in Vietnam.
VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (PINKSHEETS:VPTDF) has released its latest version of the VMS™ heart analysis system.